Corvus CPI-444 Data Disappoints at AACR 2017
Washington DC – this is our final daily post from the 2017 annual meeting of the American Association for Cancer Research (AACR).
Starting on Monday we’ll be writing up expert interviews and providing commentary and analysis around some of the sessions we went to and the data we heard.
Tuesday at AACR17 was a day when the Corvus Pharmaceuticals stock dropped 50% following presentation of preliminary clinical data for their A2A receptor antagonist CPI-444.
It’s hard not to be disappointed when you see the waterfall plots skewed to the left and above the X axis, but we really don’t have enough data yet to determine whether CPI-444 on it’s own or in combination with atezolizumab may offer benefit to some cancer patients and if so, which ones.
Dr Leisha Emens JHU presents first atezo + CPI-444 combo data. RCC & NSCLC cohorts expanded in single arm & atezo + CPI-444 arms. #AACR17 pic.twitter.com/lE4PU9Ee3X
— Pieter Droppert (@3NT) April 4, 2017
The company have expanded the renal (RCC) and lung cohorts (NSCLC) in their initial trial, and they’ve told us to expect more data at ASCO17 in a few weeks time. Small cap biotech stocks can be a roller coaster when it comes to data presentations at major medical/scientific meetings.
$CRVS went from $13 to $23 in 3 weeks
and from $20 to $11 in 30 minutes
small cap #biotech in a nutshell— Dan Rosenblum (@sharkbiotech) April 4, 2017
What else caught our attention in the sessions we attended on Tuesday at #AACR17?
Subscribers can login to read more
This content is restricted to subscribers
